The Chemours Company
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $5.81B | $5.78B | $6.08B | $6.83B | $6.35B | $4.97B | $5.53B |
| Cost of Revenue | — | $4.91B | $4.64B | $4.78B | $5.22B | $4.96B | $3.90B | $4.46B |
| Gross Profit | — | $902.0M | $1.14B | $1.30B | $1.62B | $1.38B | $1.07B | $1.06B |
| Gross Margin | — | 15.5% | 19.8% | 21.4% | 23.7% | 21.8% | 21.5% | 19.2% |
| Operating Expenses | ||||||||
| Research & Development | — | $108.0M | $109.0M | $108.0M | $118.0M | $107.0M | $93.0M | $80.0M |
| SG&A Expense | — | $799.0M | $598.0M | $1.29B | $710.0M | $592.0M | $527.0M | $548.0M |
| Operating Income | — | $-8.0M | $369.0M | $-110.0M | $904.0M | $861.0M | $389.0M | $84.0M |
| Operating Margin | — | -0.1% | 6.4% | -1.8% | 13.2% | 13.6% | 7.8% | 1.5% |
| Interest Expense | — | $269.0M | $263.0M | $208.0M | $163.0M | $185.0M | $210.0M | $208.0M |
| Pretax Income | — | $-277.0M | $106.0M | $-318.0M | $741.0M | $676.0M | $179.0M | $-124.0M |
| Income Tax Expense | — | $109.0M | $37.0M | $-66.0M | $163.0M | $68.0M | $-40.0M | $-72.0M |
| Net Income | — | $-386.0M | $69.0M | $-253.0M | $578.0M | $608.0M | $219.0M | $-52.0M |
| Net Margin | — | -6.6% | 1.2% | -4.2% | 8.5% | 9.6% | 4.4% | -0.9% |
| EPS (Basic) | — | $-2.57 | $0.46 | $-1.70 | $3.72 | $3.69 | $1.33 | $-0.32 |
| EPS (Diluted) | — | $-2.57 | $0.46 | $-1.70 | $3.65 | $3.60 | $1.32 | $-0.32 |
| Shares Outstanding (Basic) | 150.1M | 150.2M | 149.5M | 148.9M | 155.4M | 164.9M | 164.7M | 164.8M |
| Shares Outstanding (Diluted) | 150.1M | 150.2M | 150.2M | 148.9M | 158.3M | 168.7M | 166.3M | 164.8M |
| Dividends Per Share | — | $0.51 | $1.00 | $1.00 | $1.00 | $1.00 | $1.00 | $1.00 |